Carole Seguin‐Devaux

This study develops and tests a dual strategy using NaMiX and TriKE to enhance NK cell cytotoxicity against PDAC, showing improved tumor cell killing in vitro and in humanized mouse models.

This study develops humanized glioblastoma PDOX models to study tumor-immune interactions and test immunotherapies in a human context.

This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.